SML2225
RO5263397
≥98% (HPLC), TAAR1 agonist, powder
别名:
(S)-4-(3-Fluoro-2-methyl-phenyl)-4,5-dihydro-oxazol-2-ylamine
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C10H11FN2O
化学文摘社编号:
分子量:
194.21
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
RO5263397, ≥98% (HPLC)
InChI
1S/C10H11FN2O/c1-6-7(3-2-4-8(6)11)9-5-14-10(12)13-9/h2-4,9H,5H2,1H3,(H2,12,13)/t9-/m1/s1
InChI key
IOHOUWIYOVWGHV-SECBINFHSA-N
SMILES string
NC1=N[C@@H](C2=CC=CC(F)=C2C)CO1
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D +77 to +88°, c = 1.0 in methanol
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
Orally available, potent and selective partial TAAR1 agonist with similar in vivo efficacy as the full agonist RO5256390.
RO5256390 is an orally available partial agonist that targets trace amine-associated receptor 1 (TAAR1) with high affinity (Ki in nM = 0.9/mouse, 4.1/human, 9.1/rat, 24/monkey TARR1), potency (EC50 in nM/relative efficacy with respect to β-phenylethylamine = 1.3/0.59/mouse, 17/0.81/human, 47/0.76/rat, 251/0.85/monkey TARR1-dependent cellular cAMP production), and selectivity (by a 112-receptor/channel/transporter and a 42-enzyme panel), without agonistic activity toward mouse TAAR4-expressing cells even at a high concentration of 30 μM. When applied via oral administration (0.003-1 mg/kg), RO5256390 exhibits similar in vivo efficacy as the full agonist RO5256390 in blocking psychostimulants-induced hyperlocomotion in mice.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Guido Galley et al.
ACS medicinal chemistry letters, 7(2), 192-197 (2016-03-18)
2-Aminooxazolines were discovered as a novel structural class of TAAR1 ligands. Starting from a known adrenergic compound 1, structural modifications were made to obtain highly potent and selective TAAR1 ligands such as 12 (RO5166017), 18 (RO5256390), 36 (RO5203648), and 48
Artem Dorotenko et al.
Cellular and molecular neurobiology, 40(2), 215-228 (2019-11-18)
Trace amine-associated receptor 1 (TAAR1) is a widely recognized new perspective target for the neuropsychiatric pharmacological treatment. Despite a growing number of studies investigating TAAR1 role in the animal models of different pathologies, information of TAAR1 agonists impact on executive
Sarah W Black et al.
Biological psychiatry, 82(9), 623-633 (2016-12-07)
Narcolepsy, a disorder of rapid eye movement (REM) sleep, is characterized by excessive daytime sleepiness and cataplexy, a loss of muscle tone triggered by emotional stimulation. Current narcolepsy pharmacotherapeutics include controlled substances with abuse potential or drugs with undesirable side
F G Revel et al.
Molecular psychiatry, 18(5), 543-556 (2012-05-30)
Schizophrenia is a chronic, severe and highly complex mental illness. Current treatments manage the positive symptoms, yet have minimal effects on the negative and cognitive symptoms, two prominent features of the disease with critical impact on the long-term morbidity. In
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持